Nautilus Biotechnology (NAUT) Assets Average (2020 - 2026)

Nautilus Biotechnology has disclosed Assets Average across 7 years of filings, most recently posting $184.4 million for Q1 2026.

• Assets Average for Q1 2026 came in at $184.4 million, down 21.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $184.4 million (down 21.58% YoY), and the FY2025 annual result was $216.9 million, down 20.87% from the prior year.
• Assets Average came in at $184.4 million for Q1 2026 at Nautilus Biotechnology, down from $196.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $391.6 million in Q1 2022 to a low of $184.4 million in Q1 2026.
• The 5-year median for Assets Average is $297.1 million (2024), against an average of $291.2 million.
• Across the five-year window, Assets Average surged 232.52% in 2022 and slipped 22.23% in 2025, its largest moves.
• Nautilus Biotechnology's Assets Average stood at $354.7 million in 2022, then fell by 12.05% to $312.0 million in 2023, then fell by 19.47% to $251.2 million in 2024, then fell by 21.98% to $196.0 million in 2025, then retreated by 5.9% to $184.4 million in 2026.
• The last three Assets Average figures came in at $184.4 million (Q1 2026), $196.0 million (Q4 2025), and $207.1 million (Q3 2025), per Business Quant data.